Allos Therapeutics, Inc. Executive Compensation Determination for 2007–2008
Allos Therapeutics, Inc.'s Compensation Committee approved 2007 cash bonuses, 2008 base salaries, and 2008 target bonus percentages for its named executive officers. The Chief Executive Officer's 2008 target bonus was also approved by the full Board. The agreement outlines the specific compensation amounts and bonus targets for each executive, including the CEO, CMO, CCO, General Counsel, and VP of Finance. This document formalizes the company's executive pay structure for the specified period.
Exhibit 10.1
Executive Compensation
At a meeting of the Compensation Committee of the Board of Directors of Allos Therapeutics, Inc. (the “Company”) held on February 25, 2008, the Compensation Committee determined and approved 2007 cash bonus awards and 2008 base salaries and target bonus awards (expressed as a percentage of base salary) for the Company’s “named executive officers” (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission) as set forth in the table below. The 2008 target bonus award (expressed as a percentage of base salary) for the Chief Executive Officer was also reviewed and approved by the full Board of Directors at a meeting held on February 25, 2008.
| Name and Title |
| 2007 |
| 2008 |
| 2008 |
| ||
| Paul L. Berns |
| $ | 280,752 |
| $ | 500,850 |
| 60% |
|
| Pablo J. Cagnoni, M.D. |
| $ | 124,997 |
| $ | 404,250 |
| 40% |
|
| James V. Caruso |
| $ | 154,857 |
| $ | 398,580 |
| 40% |
|
| Marc H. Graboyes |
| $ | 73,210 |
| $ | 300,583 |
| 30% |
|
| David C. Clark |
| $ | 53,166 |
| $ | 210,000 |
| 25% |
|
